Phenylbutazone

Phenylbutazone (CAS No.: 50-33-9) is a synthetic non-steroidal anti-inflammatory drug widely utilized in biomedical research as a prototypical modulator of inflammatory pathways and prostaglandin biosynthesis. It functions primarily through inhibition of cyclooxygenase-associated peroxidase activity and prostaglandin I synthase, exhibiting inhibitory effects in the low to mid micromolar range under oxidative conditions, and also serves as a reducing cofactor for prostaglandin H synthase, thereby influencing prostanoid production. In addition to its classical anti-inflammatory activity, phenylbutazone has been shown to modulate gene expression, including induction of muscleblind-like protein 1, supporting its utility in studies of RNA splicing regulation and musculoskeletal or inflammatory disorders such as ankylosing spondylitis. Although historically used for the management of chronic pain and arthritis symptoms and in veterinary models of joint inflammation, its hepatotoxic potential necessitates careful experimental design and interpretation. In vitro and in vivo, phenylbutazone is commonly employed to investigate inflammatory signaling cascades, extracellular matrix remodeling, and prostaglandin-mediated responses, with experimental concentrations or dosing regimens adjusted according to specific cellular systems or animal models, including studies of synovitis and cartilage-associated biomarkers.